China · Delayed Price · Currency is CNY Hinova Pharmaceuticals Company Description
Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, develops and produces therapeutics for cancers and metabolic syndromes.
Its core product is Hainaan, a deuterium enzalutamide soft capsules for the treatment of prostate cancer; it also develops drugs based on proteolysis targeting chimera and deuteration technology.
The company’s products pipeline includes HP518, a PROTAC molecule targeting advanced prostate cancer; HP537, a small-molecule anti-tumor drug; HP515, an orally administered which improves liver and blood biochemical indicators; HP570, an orally administered molecular gel degrader targeting VAV1; and HC-X049, a small molecule project with STAT6 target layout.
Hinova Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Chengdu, China.
| Country | China |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 241 |
| CEO | Yuanwei Chen |
Contact Details
Address: Building 1, Rongyao Building Chengdu, 610041 China | |
| Phone | 86 28 8505 8465 |
| Website | hinovapharma.com |
Stock Details
| Ticker Symbol | 688302 |
| Exchange | Shanghai Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE1000059F5 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Yuanwei Chen Ph.D. | Chairman of the Board and General Manager |
| Xinghai Li M.D., Ph.D. | Co-Founder, Chief Technology Officer and Director |
| Li Dai | Vice President of Operations, Secretary and Director |
| Ze Yan Shi | Financial Director |
| Jun Hu | Accounting Supervisor |
| Tango Tang | Vice President of Marketing |
| Lei Fan | Senior Vice President of Pharmaceutical Chemistry |
| Wu Du | Senior Vice President of Pharmaceutical Chemistry |
| Tong Tao Kuang | Vice President of CMC |